SR9009 (Stenabolic)

SR9009 (Stenabolic) is a synthetic REV-ERB agonist (not a peptide) that influences circadian rhythm regulation and metabolic processes. REV-ERB proteins are nuclear receptors that control the expression of genes involved in lipid and glucose metabolism, inflammation, and circadian rhythms. Research demonstrates SR9009 increases exercise capacity, enhances fat oxidation, decreases cholesterol and triglycerides, and reduces inflammation in animal models. The compound effectively mimics some benefits of exercise by activating REV-ERB-dependent metabolic programs. Studies show improved endurance without actual exercise training and beneficial effects on body composition. SR9009 may also influence sleep-wake cycles through its circadian effects. However, the compound has very poor oral bioavailability, limiting its practical application. Like Cardarine, SR9009 is often grouped with research peptides and SARMs in fitness communities despite being a different class of compound. It is banned by WADA for competitive sports. Long-term safety data in humans is lacking, and caution is warranted given limited clinical research.

All efficacy data come from rodent studies; there are no human trials, and SR9009 has very poor oral bioavailability (commonly reported ~2%), which limits its practical relevance. Long-term safety is unknown. It is an investigational tool compound, not a peptide, and not approved anywhere.

SR9009 (stenabolic) is a small-molecule agonist of the REV-ERB-α/β nuclear receptors, not a peptide. It suppresses BMAL1 transcription, altering circadian gene expression and metabolic programs (increased energy expenditure, oxidative metabolism). Oral bioavailability is very poor (~2% reported in literature), which is a major practical limitation; typical research use is parenteral.